An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Completed · Phase 2
Conditions studied: Lung Disease, Pulmonary Fibrosis
In brief
Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.
Key facts
- Study ID
- NCT00052052
- Run by
- InterMune
- People needed
- 210
- Starts
- 2002-09-01
- Expected to finish
- 2004-09-01
- Last updated by the study team
- 2007-11-06
Who can join
Age: 20 and older, up to 79. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Washington Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.